Follow the entities shaping the evidence.

… SC maintenance (100 mg q8w or 200 mg q4w). GRAVITI assessed SC GUS induction (400 mg at W0, W4, and W8) and the same GUS maintenan…

…Introduction Guselkumab (GUS) is a dual-acting IL-23p19 subunit inhibitor that potently…

…Introduction Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate …

…Introduction Upadacitinib (UPA) is an oral, reversible Janus tyrosine kinase inhibitor (J…

…1.3%) had T2DM. Patients with T2DM were more likely suffer from chronic pulmonary disease, chronic renal failure, heart failure, liver disease and hypert…

…ived from BSG guidance and received an OGD prior to initiation. Sucralfate has shown to have a positive effect on patient’s endoscopic fin…

… gut barrier is impaired in numerous health disorders including coeliac disease, inflammatory bowel disease (IBD), liver disease, and environme…

…meability assessment across 4 days in a prospective study. Oral indomethacin was used to induce increased small bowel permeability. Baseline…

…tely 1 in 7 adults in the USA and UK. Our findings suggest that NCGS may represent a broader syndrome of food-related symptom attrib…

…ith diarrhoea (IBS-D), who show additional symptom benefit with ondansetron.Pre-clinical models have confirmed that INSL5 is pro-motility w…

….8%) with advanced fibrosis and 17 (0.7%) with cirrhosis (total cACLD 61 [2.5%]). The proportion of people with cACLD was 6.5% (43) i…

…n (B), ALP % change from BL (C) through 36 months of open-label seladelpar treatmentn/N = number of responders at each time point/total nu…